Hello Guest, Welcome To The Psoriasis Club Forum. We are a self funded friendly group of people who understand.
Never be alone with psoriasis, come and join us. (Members have more privileges) LoginRegister
Psoriasis Club is a friendly on-line Forum where people with psoriasis or psoriatic arthritis
can get together and share information, get the latest news, or just chill out with others who understand. It is totally
self funded and we don't rely on drug manufacturers or donations. We are proactive against Spammers,
Trolls, And Cyberbulying and offer a safe friendly atmosphere for our members.
So Who Joins Psoriasis Club?
We have members who have had psoriasis for years and some that are newly diagnosed. Family and friends of those with psoriasis
are also made welcome. You will find some using prescribed treatments and some using the natural approach. There are people who
join but keep a low profile, there are people who just like to help others, and there are some who just like
to escape in the Off Topic Section.
Joining Couldn't Be Easier: If you are a genuine person who would like to meet others who understand,
just hit the Register button and follow the instructions.
Members get more boards and privileges that are not available to guests.
OK So What Is Psoriasis?
Psoriasis is a chronic, autoimmune disease that appears on the skin. It
occurs when the immune system sends out faulty signals that speed up the
growth cycle of skin cells. Psoriasis is not contagious. It commonly
causes red, scaly patches to appear on the skin, although some patients
have no dermatological symptoms. The scaly patches commonly caused by
psoriasis, called psoriatic plaques, are areas of inflammation and
excessive skin production. Skin rapidly accumulates at these sites which
gives it a silvery-white appearance. Plaques frequently occur on the
skin of the elbows and knees, but can affect any area including the
scalp, palms of hands and soles of feet, and genitals. In contrast to
eczema, psoriasis is more likely to be found on the outer side of the
joint.
The disorder is a chronic recurring condition that varies in severity
from minor localized patches to complete body coverage. Fingernails and
toenails are frequently affected (psoriatic nail dystrophy) and can be
seen as an isolated symptom. Psoriasis can also cause inflammation of
the joints, which is known as (psoriatic arthritis). Ten to fifteen
percent of people with psoriasis have psoriatic arthritis.
The cause of psoriasis is not fully understood, but it is believed to
have a genetic component and local psoriatic changes can be triggered by
an injury to the skin known as Koebner phenomenon. Various
environmental factors have been suggested as aggravating to psoriasis
including stress, withdrawal of systemic corticosteroid, excessive
alcohol consumption, and smoking but few have shown statistical
significance. There are many treatments available, but because of its
chronic recurrent nature psoriasis is a challenge to treat. You can find more information
Here!
Got It, So What's The Cure?
Wait Let me stop you there! I'm sorry but there is no cure. There are things that can help you
cope with it but for a cure, you will not find one.
You will always be looking for one, and that is part of the problem with psoriasis There are people who know you will be
desperate to find a cure, and they will tell you exactly what you want to hear in order to get your money. If there is a
cure then a genuine person who has ever suffered with psoriasis would give you the information for free. Most so called cures
are nothing more than a diet and lifestyle change or a very expensive moisturiser. Check out the threads in
Natural Treatments first and save your money.
Great so now what? It's not all bad news, come and join others at Psoriasis Club and talk about it. The best help is from accepting it and talking
with others who understand what you're going through. ask questions read through the threads on here and start claiming
your life back. You should also get yourself an appointment with a dermatologist who will help you find something that can
help you cope with it. What works for some may not work for others
Hi All
I am so pleased I registered with the Psoriasis Club. Just reading the comments posted by fellow sufferers as eased my mind regarding my current treatment.
I have recently stopped using methotrexate after 1 year due to the effects it was having on my liver and was prescribed Fumaderm in July 2012. I am currently on 2 Blue tablets per day and the stomach cramps are already unbearable. I was contemplating stopping this treatment but my psoriasis is at an all-time high.
Is there any other treatment I could consider?
Danny
Posted by: Fred - Tue-21-08-2012, 11:46 AM
- No Replies
Objective:
To assess whether patients with psoriasis treated with tumor necrosis factor (TNF) inhibitors have a decreased risk of *myocardial infarction (MI) compared with those not treated with TNF inhibitors.
Design:
Retrospective cohort study.
Setting:
Kaiser Permanente Southern California health plan.
Patients:
Patients with at least 3 International Classification of Diseases, Ninth Revision, Clinical Modification, codes for psoriasis (696.1) or psoriatic arthritis (696.0) (without antecedent MI) between January 1, 2004, and November 30, 2010.
Main Outcome Measure:
Incident MI.
Results:
Of 8845 patients included: 1673 received a TNF inhibitor for at least 2 months (TNF inhibitor cohort), 2097 were TNF inhibitor naive and received other systemic agents or phototherapy (oral/phototherapy cohort), and 5075 were not treated with TNF inhibitors, other systemic therapies, or phototherapy (topical cohort). The median duration of follow-up was 4.3 years (interquartile range, 2.9-5.5 years), and the median duration of TNF inhibitor therapy was 685 days (interquartile range, 215-1312 days). After adjusting for MI risk factors, the TNF inhibitor cohort had a significantly lower hazard of MI compared with the topical cohort (adjusted hazard ratio, 0.50; 95% CI, 0.32-0.79). The incidence of MI in the TNF inhibitor, oral/phototherapy, and topical cohorts were 3.05, 3.85, and 6.73 per 1000 patient-years, respectively.
Conclusions:
Use of TNF inhibitors for psoriasis was associated with a significant reduction in MI risk and incident rate compared with treatment with topical agents. Use of TNF inhibitors for psoriasis was associated with a non–statistically significant lower MI incident rate compared with treatment with oral agents/phototherapy.
Source: archderm.jamanetwork.com
*Myocardial Infarction (MI) is commonly known as a heart attack.
Posted by: Hanna - Mon-20-08-2012, 16:14 PM
- Replies (1)
This has really frustrated me today and played on my mind a lot, so I just want to vent a bit.
I know deep down I should know better and not judge and I feel like a bad person!
I had a call today from someone who needed to re-home their dog which they have had the past 5 years, their reason Psoriasis!!!v
As a dog lover and owner and a sufferer of the condition it has really struck a cord with me.
I have been so bad to the point I cannot dress myself but I do and I just push on through and still I manage to walk my dog and care for him, I also know that if I am very bad there are treatments and it's only a matter of time before I can start and the meds kick in.
I feel awful for my lack of sympathy but I get so many phone calls about people needing to re-home. And if the person who called is reading this I do apologise I don't know your own situation and I really hope you find relief soon.
Posted by: susan - Sun-19-08-2012, 18:20 PM
- Replies (2)
I used Dovonex when it first came out and omg I was in agony the itching was unbearable. Had Diprosalic, dithranol in lassars paste all strengths, methatrexate, and the only thing I used which cleared my skin within a week was Psorigan and as it was only cosmetically approved and not medically approved it was taken off the market. I wish I had bought loads of it at the time. Also had PUVA and ultra violet and at moment using a solution of coal tar and aqueous solution.
Posted by: susan - Sun-19-08-2012, 17:34 PM
- Replies (4)
Hi all, yesterday I said I received an email from someone called billy who was a mechanic. He was in despair and was thinking of blowing his head off. he said the psoriasis was in his finger nails and toenails and sounded so distraught. I did reply to him through a yahoo email. Unfortunately I cannot find it to copy and paste for you all to see. I tried to say to him that it was harder for a female especially in this hot weather as I cannot wear shoes as the pressure hurts my toes and wearing sandals is a definate no no for me. Maybe I said the wrong thing to him and now I am a bit worried because if he is not a member here then why did I get the email. please help
Posted by: Fred - Sun-19-08-2012, 15:03 PM
- Replies (2)
A Rochester Institute of Technology NY (RIT) team is seeking to improve the diagnosis and assessment of psoriasis through the creation of a multimodal, image-based analysis system. The project seeks to improve treatment for individual patients and allow for enhanced longitudinal studies of psoriasis.
"Presently, dermatologists use a method called the Psoriasis Area Severity Index (PASI) score to analyze affected areas of the skin," notes Christye Sisson, professor of biomedical photography at RIT and leader of the project team. "However, the process can be very subjective as each dermatologist could potentially 'grade' patients differently."
The lack of empirical data can make it difficult to compare assessments made by different dermatologists or by different research groups studying the disease.
"Through the use of novel imaging technologies we are seeking to create a standardized and repeatable process that will be more accurate and allow for better assessment across populations," Sisson adds.
Sisson is working with Francisco Tausk, MD, a professor of dermatology at University of Rochester Medical Center, to create an imaging tool based on anomaly detection software which has previously been used in remote sensing applications. The tool will include multiple imaging modalities and assess the area of coverage based on the three criteria currently used by the PASI score: thickness, redness, and scale.
The team is currently testing imaging techniques, including thermal, ultra violet reflectance, and LIDAR, to identify the best method for assessing each criteria. They will then work with the University of Rochester to assess severity on current psoriasis patients and compare it to the PASI scores for each person.
Sisson and Tausk hope to ultimately create a standardized multimodal imaging system that could be implemented by dermatologists and hospitals nationwide.
"By modifying imaging technology that has already been developed we can create a repeatable, quantifiable method for diagnosing and ultimately treating patients with this disease," Sisson says.
Posted by: joodles - Sat-18-08-2012, 01:10 AM
- Replies (3)
Hi, new here, I developed Psoriasis at 10/11 years old, it went mad in my mid teens then disappeared, has now flared up again over the last two years & just wondering if hormones are a key factor as I have been going through menapause?"wave"
Posted by: Hanna - Sat-11-08-2012, 18:41 PM
- Replies (6)
In case you didn't know August is psoriasis awareness week in USA.
Lots of details are on facebook (national psoriasis association) they are also running a photo competition!
I couldn't enter as in the UK but I posted my first ever psoriasis showing picture on Facebook to get into the spirit of things!
Posted by: Fred - Fri-10-08-2012, 23:15 PM
- No Replies
Perrigo Company today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for clobetasol propionate shampoo, 0.05%, the generic equivalent of Clobex® Shampoo. Perrigo will commence shipment of the product immediately.
Clobetasol propionate shampoo, 0.05%, is indicated for the treatment of moderate to severe scalp psoriasis. Perrigo's Chairman, President and CEO Joseph C. Papa stated, "This is another example of our Rx team's commitment to launching difficult to manufacture extended topical products. We are excited to market this product and are dedicated to making quality healthcare more affordable."
Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, and active pharmaceutical ingredients (API). The Company is the world's largest manufacturer of OTC pharmaceutical products and infant formulas, both for the store brand market. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia.
Posted by: Fred - Fri-10-08-2012, 22:45 PM
- No Replies
Background:
Despite widespread dissatisfaction and low treatment persistence in moderate to severe psoriasis, patients' reasons behind treatment discontinuation remain poorly understood.
Objectives:
We sought to characterize patient-reported reasons for discontinuing commonly used treatments for moderate to severe psoriasis in real-world clinical practice.
Methods:
A total of 1095 patients with moderate to severe plaque psoriasis from 10 dermatology practices who received systemic treatments completed a structured interview. Eleven reasons for treatment discontinuation were assessed for all past treatments.
Results:
A total of 2231 past treatments were reported. Median treatment duration varied by treatment, ranging from 6.0 to 20.5 months (P < .001). The frequency of each cited discontinuation reasons differed by treatment (all P < .01). Patients who received etanercept (odds ratio [OR] 5.19; 95% confidence interval [CI] 3.23-8.33) and adalimumab (OR 2.10; 95% CI 1.20-3.67) were more likely to cite a loss of efficacy than those who received methotrexate. Patients who received etanercept (OR 0.34; 95% CI 0.23-0.49), adalimumab (OR 0.48; 95% CI 0.30-0.75), and ultraviolet B phototherapy (OR 0.21; 95% CI 0.14-0.31) were less likely to cite side effects than those who received methotrexate, whereas those who received acitretin (OR 1.56; 95% CI 1.08-2.25) were more likely to do so. Patients who underwent ultraviolet B phototherapy were more likely to cite an inability to afford treatment (OR 7.03; 95% CI 3.14-15.72).
Conclusions:
Different patterns of treatment discontinuation reasons are important to consider when developing public policy and evidence-based treatment approaches to improve successful long-term psoriasis control.
Posted by: Fred - Fri-10-08-2012, 11:49 AM
- No Replies
GlaxoSmithKline and Rosa to Present Psoriasis Collaboration Results at 17th International IRA Conference.
Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that results from its Psoriasis PhysioPD collaboration with Stiefel, a GSK Company, will be presented at the 17th International Inflammation Research Association Conference in Lake George, NY, September 9-13th, 2012. Dr. Betty Hussey, Director, Clinical Pharmacology of GSK will present a poster entitled "Physiological model to investigate and prioritize targets for psoriasis".
The presentation will describe the development and use of a custom-designed Psoriasis PhysioMap® which provided information and methodology to enable key decisions in early development target prioritization. The map was built using literature data and then critically reviewed by R&D scientists and disease experts. The presentation will show how the map was used to evaluate the roles of drug targets in disease pathways, their potential interactions, and their relative contributions to efficacy potential. This process has informed the selection and prioritization of drug development targets, and it set the stage for development of a quantitative PhysioPD model that will further elucidate and prioritize target potential.
"We are pleased to share the initial results from our ongoing collaboration with GSK", said Dr. Rebecca Baillie, Chief Scientist, PhysioPD at Rosa. "The results of this collaboration show the business value and scientific usefulness of developing a Psoriasis PhysioMap. The PhysioMap development process was critical for establishing a common understanding of the key data and material uncertainties relevant to psoriasis and providing a framework to facilitate cross-functional communication within GSK."
Reading the most recent posts regarding Fumaderm and those trying the product for the first time, I encourage you to continue. Stomach cramping seems to be the most traumatic side effect but well worth the tolerance to achieve the benefits of Fumaderm. What do you take to alleviate the cramping? I used antacids.
As reported previously, I was a +30 year sufferer of Psoriasis, ran the gamut of controls available in Canada and USA except for biologic treatments, and today am totally free of the disease. Some days, it is unbelievable to think back on the severity of the affliction and have no Psoriasis today. I have some scarring, mostly slight discoloration of previous Psoriasis sites, but that's it.
I went through the step-up program, then step-down to a maintenance program of 1 x 120 mg per day for the past 2-1/2 years.
A peculiarity of the disease is that not all treatments work for all people, but my experience prompts me to advise you to try it or stick with it if you are already one the medication.
Posted by: Farmboy - Tue-07-08-2012, 02:03 AM
- Replies (7)
Hi everyone, like my username says, I'm just a farmboy from Canada My question to the forum is this: How genetically heritable is psoriasis? My mom has it on her elbows, neck, back and knees, and she is in a quite a bit of discomfort all the time.
Posted by: Fred - Mon-06-08-2012, 20:15 PM
- No Replies
Sandoz launches first-to-file calcipotriene cream, the first generic.
Sandoz, a Division of the Novartis group, is the second-largest generic pharmaceuticals company globally, offering a broad range of about 1000 high-quality, affordable products that are no longer protected by patents. announces the introduction of its first-to-file calcipotriene cream, the first generic version of LEO Pharma Inc.’s Dovonex® Cream, 0.005% in the US.
"Sandoz is proud to be both the first company to file for and the first to launch this important new generic dermatology medicine, which further strengthens Sandoz’s #1 position in generic dermatology medicines in the US and globally,” said Don DeGolyer, President of Sandoz US. “The launch of calcipotriene cream further demonstrates our commitment to improving patient access to high-quality, affordable medicines.”
According to IMS Health, US sales for the branded version of calcipotriene cream were approximately USD 118.8 million for the 12 months ending in May 2012. Sandoz is marketing calcipotriene in the 0.005% strength, the same strength that is marketed as Dovonex® Cream, 0.005%.
Currently Sandoz has a total of 172 ANDAs (Abbreviated New Drug Applications) pending approval with the US FDA, including 40 confirmed first-to-file opportunities.
Posted by: Fred - Wed-01-08-2012, 12:22 PM
- No Replies
Can-Fite BioPharma expects to publish positive data at the end of the third quarter regarding the safety and efficacy of its CF101 drug under development for the treatment of psoriasis, the Israeli company's acting CEO said on today.
CF101, a small molecule oral drug, is in advanced clinical development for the treatment of autoimmune inflammatory diseases such as psoriasis, and rheumatoid arthritis.
Can-Fite acting CEO and founder Pnina Fishman said the company was conducting a Phase II/III clinical study involving 300 patients in the United States, Europe and Israel.
"We are going to have the interim analysis clinical data towards the end of the third quarter," Fishman told Reuters. "The data is positive ... in terms of safety and efficacy."
Shares in Can-Fite were up 3.8 percent in midday Tel Aviv trade after the clinical trial's investigators presented their findings to investors.
The most effective treatments for psoriasis on the market are biological drugs focused on blocking the inflammatory factor in the body that causes the disease.
Though the drugs are effective, patients may suffer from adverse events that can cause inflammatory conditions as well as depression and sepsis, Fishman said. The cost of treatment per patient is about $20,000 a year and over time patients can stop responding to the drugs.
"There is a need for another type of drug that won't be so expensive and will not induce adverse events," Fishman said.
CF101 is administered as a tablet twice daily while the biological drugs must be administered intravenously.
"We will position it in the market so that the margin of profit will be high for the company but the cost will be much, much lower than for the biological drugs," Fishman said.
Can-Fite will need to conduct a Phase III study in addition to the Phase II/III study underway to obtain approval from the U.S. Food and Drug Administration. Fishman estimated it would take three to four years to register the drug.
About 2 percent of the world's population suffers from psoriasis and the market for treatment of the disease is valued at $3.6 billion a year worldwide. This is estimated to grow to $8.5 billion by 2017.
Can-Fite has licensed CF101 for the treatment of autoimmune diseases to Seikagaku Corp in Japan and for rheumatoid arthritis to Kwang Dong in South Korea. Can-Fite so far has received $8.5 million in upfront payments.
"There never will be a cure for psoriasis but we would like to turn it into a disease where the clinical manifestations will be minimal," Fishman said.
Hi I,m new here, so hello everyone. I have psoriatic arthritis with psoriasis. 7 weeks ago my legs were burning so bad and I assumed I was just having a flare up, but that night when I got home and removed my compression stockings, my legs were swollen, sore and bright pink from the feet to my knees on both legs. I went straight to the ER where I received an IV with antibiotics. Diagnosis, Cellulitis with the psoriasis. It has been 7 weeks and I am still on the antibiotics. A nurse comes to my home and administers antibiotic IV drip each morning. Having psoriasis of the legs I don't know what is now the psoriasis and what is the cellulitis. I wondered if anyone on the forum has ever had cellutitis and if so could the please give me a little info on how long they were on the antibiotics and so on. My legs are still pink and burning, the feeling reminds me of when I have a flare up with my psoriasis, I'm feeling so depressed and don't see much difference in 7 weeks.
Sorry my post is so long, would appreciate if anyone has any info. All these years I thought that having psoriasis is bad, but this is the worst.
Posted by: Fred - Fri-27-07-2012, 14:06 PM
- No Replies
Horizon Pharma, Inc announced today that the U.S. Food and Drug Administration (FDA) has approved RAYOS® known as LODOTRA® in Europe (prednisone) delayed-release tablets (1 mg, 2 mg and 5 mg) to treat a broad range of diseases including rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), psoriatic arthritis (PsA), ankylosing spondylitis (AS), asthma and chronic obstructive pulmonary disease (COPD)
"We are extremely pleased the FDA has approved RAYOS for a broad range of indications, including RA and polymyalgia rheumatica,” said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma. “Our initial focus will be on the launch of RAYOS in rheumatologic diseases such as RA and polymyalgia rheumatica in the fourth quarter of this year. Based on the extent of the approved indications, we will be developing a broader commercial strategy to expand the opportunity for RAYOS in key IL-6 mediated diseases, including asthma and COPD."
"Prednisone is a common therapy for patients with various inflammatory diseases, including RA, and the delayed-release enhancement offered with RAYOS is an important treatment advance,” said Michael Schiff, M.D., Clinical Professor of Medicine at the University of Colorado School of Medicine, Rheumatology Division. “RAYOS is engineered to benefit the underlying patterns of inflammatory diseases. RAYOS, as studied in its clinical trials with ten p.m. dosing, reduces the overnight rise of inflammatory mediators, which results in less pain and stiffness for patients as they begin their day."
Important information about RAYOS
Do not use RAYOS if you are allergic to prednisone.
Long-term use of RAYOS can affect how your body responds to stress. Symptoms can include weight gain, severe fatigue, weak muscles, and high blood sugar.
RAYOS can weaken your immune system, making it easier for you to get an infection or worsening an infection you already have or have recently had.
RAYOS can cause high blood pressure, salt and water retention and low blood potassium.
There is an increased risk of developing holes in the stomach or intestines if you have certain stomach and intestinal disorders.
Behavior and mood changes can occur, including intense excitement or happiness, sleeplessness, mood swings, personality changes or severe depression.
Long-term use of RAYOS can cause decreases in bone density.
RAYOS can cause cataracts, eye infections and glaucoma.
Do not receive a "live" vaccine while taking RAYOS. The vaccine may not work as well during this time, and may not fully protect you from disease.
Taking RAYOS during the first trimester of pregnancy can harm an unborn baby.
Long-term use of RAYOS can slow growth and development in children.
The most common side effects with RAYOS are water retention, high blood sugar, high blood pressure, unusual behaviour and mood changes, increased appetite and weight gain.
Posted by: Fred - Thu-26-07-2012, 19:15 PM
- No Replies
A new study suggests that Methotrexate may not be helping *Synovitis in Psoriatic Arthritis.
Objective:
MTX (Methotrexate) is widely used to treat synovitis in PsA (Psoriatic Arthritis) without supporting trial evidence. The aim of our study was to test the value of MTX in the first large randomized placebo-controlled trial (RCT) in PsA.
Methods:
A 6-month double-blind RCT compared MTX (15 mg/week) with placebo in active PsA. The primary outcome was PsA response criteria (PsARC). Other outcomes included ACR20, DAS-28 and their individual components. Missing data were imputed using multiple imputation methods. Treatments were compared using logistic regression analysis (adjusted for age, sex, disease duration and, where appropriate, individual baseline scores).
Results: Four hundred and sixty-two patients were screened and 221 recruited. One hundred and nine patients received MTX and 112 received placebo. Forty-four patients were lost to follow-up (21 MTX, 23 placebo). Twenty-six patients discontinued treatment (14 MTX, 12 placebo). Comparing MTX with placebo in all randomized patients at 6 months showed no significant effect on PsARC [odds ratio (OR) 1.77, 95% CI 0.97, 3.23], ACR20 (OR 2.00, 95% CI 0.65, 6.22) or DAS-28 (OR 1.70, 95% CI 0.90, 3.17). There were also no significant treatment effects on tender and swollen joint counts, ESR, CRP, HAQ and pain. The only benefits of MTX were reductions in patient and assessor global scores and skin scores at 6 months (P = 0.03, P < 0.001 and P = 0.02, respectively). There were no unexpected adverse events.
Conclusions:
This trial of active PsA found no evidence for MTX improving synovitis and consequently raises questions about its classification as a disease-modifying drug in PsA.
Source: nih.gov
*Synovitis is the medical term for inflammation of the synovial membrane. This membrane lines joints which possess cavities, known as synovial joints. The condition is usually painful, particularly when the joint is moved. The joint usually swells due to synovial fluid collection.
You have to register before you can post on our site.
Members Images
Join Psoriasis Club
Psoriasis Club is self funded, we don't rely on sponsorship or donations. We offer a safe
friendly forum and are proactive against spammers, trolls, and cyberbullying. Join us here!
No Advertising.
No Corprate Sponsors.
No Requests for Donations.
No Cyber-Bullying.
No Scams or Cures.
No Recruitment Posts.
No promotions or offers.
No Trolls.
No Spam.
Just a small bunch of friendly people with psoriasis sharing information and support.
Forum Statistics
» Members: 981 » Latest member: rphillips812003 » Forum threads: 7,042 » Forum posts: 254,909
There are currently 124 online users. »1 Member(s) | 122 Guest(s) "YOYO" The Psoriasis Club Bot Is On-line, Caroline
Psoriasis Cure!
How many people have Psoriasis?
In 2012 there were approximately 36.5 million prevalent cases of psoriasis, and by 2022, GlobalData epidemiologists forecast that this figure will reach approximately 40.93 million.
The condition affects individuals of both sexes and all ethnicities and ages, although there is a higher prevalence of psoriasis in the colder, northern regions of the world.
The prevalence of psoriasis in the central region of Italy is 2.8 times greater than the prevalence in southern Italy.
Caucasians have a higher prevalence of psoriasis compared with African-Americans, but African-Americans in the US tend to suffer from a more severe form of the disease.